MGNX - MacroGenics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Rockville,
United States
MGNX price evolution
MGNX
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $47.33 | $123.47 | $190.53 | $188.97 |
| Short term investments | $136.66 | $120.15 | $108.37 | $108.35 |
| Net receivables | $14.9 | $10.39 | $13.76 | $45.25 |
| Inventory | $4.6 | $4.39 | $3.98 | $6.48 |
| Total current assets | $218.2 | $279.56 | $334.7 | $367 |
| Long term investments | ||||
| Property, plant & equipment | $36.03 | $37.68 | $38.68 | $39.4 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $53.24 | $55.69 | $57.46 | $58.91 |
| Total investments | $136.66 | $120.15 | $108.37 | $108.35 |
| Total assets | $271.44 | $335.25 | $392.16 | $425.91 |
| Current liabilities | ||||
| Accounts payable | $3.73 | $15.5 | $6.17 | $9.82 |
| Deferred revenue | $31.93 | $20.65 | $25.89 | $30.04 |
| Short long term debt | $4.84 | $4.68 | $4.52 | $4.37 |
| Total current liabilities | $67.1 | $74.58 | $68.86 | $69.92 |
| Long term debt | $19.51 | $20.79 | $22.02 | $23.21 |
| Total noncurrent liabilities | $26.13 | $21.05 | $31.86 | $36.94 |
| Total debt | $24.35 | $25.47 | $26.55 | $27.57 |
| Total liabilities | $93.23 | $95.63 | $100.72 | $106.87 |
| Shareholders' equity | ||||
| Retained earnings | -$1040.38 | -$973.94 | -$915.91 | -$863.03 |
| Other shareholder equity | -$0.28 | -$0.06 | -$0 | $0 |
| Total shareholder equity | $178.21 | $239.62 | $291.44 | $319.05 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $123.47 | $181.13 | $126.47 | $220.13 |
| Short term investments | $120.15 | $91.4 | $89.28 | $12.73 |
| Net receivables | $10.39 | $23.08 | $12.74 | $29.58 |
| Inventory | $4.39 | |||
| Total current assets | $279.56 | $312.59 | $239.78 | $269.12 |
| Long term investments | ||||
| Property, plant & equipment | $37.68 | $42.23 | $48.21 | $56.71 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $55.69 | $66.15 | $72.72 | $63.01 |
| Total investments | $120.15 | $91.4 | $89.28 | $12.73 |
| Total assets | $335.25 | $378.74 | $312.5 | $332.13 |
| Current liabilities | ||||
| Accounts payable | $15.5 | $8.03 | $4.31 | $4 |
| Deferred revenue | $20.65 | $11.38 | $19.85 | $40.72 |
| Short long term debt | $4.68 | $3.99 | $3.02 | |
| Total current liabilities | $74.58 | $50.67 | $45.17 | $59.94 |
| Long term debt | $20.79 | $25.26 | $27.55 | |
| Total noncurrent liabilities | $21.05 | $32.19 | $36.71 | $29.31 |
| Total debt | $25.47 | $29.25 | $30.57 | |
| Total liabilities | $95.63 | $82.86 | $81.87 | $89.25 |
| Shareholders' equity | ||||
| Retained earnings | -$973.94 | -$771.82 | -$642.08 | -$490.27 |
| Other shareholder equity | -$0.06 | -$0.01 | $0.02 | -$0 |
| Total shareholder equity | $239.62 | $295.88 | $230.63 | $242.88 |
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $11.1 | $14.15 | $15.66 | $30.76 |
| Cost of revenue | $0.05 | $0.95 | $1.67 | $0.02 |
| Gross Profit | $11.05 | $13.2 | $14 | $30.73 |
| Operating activities | ||||
| Research & development | $61.44 | $55.85 | $49.82 | $55.78 |
| Selling, general & administrative | $16.25 | $15.58 | $17.16 | $15.23 |
| Total operating expenses | $77.69 | $71.44 | $66.98 | $71.01 |
| Operating income | -$66.64 | -$58.24 | -$52.99 | -$40.28 |
| Income from continuing operations | ||||
| EBIT | -$66.44 | -$58.02 | -$52.89 | -$39.94 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$66.44 | -$58.02 | -$52.89 | -$39.94 |
| Income (for common shares) | -$66.44 | -$58.02 | -$52.89 | -$39.94 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $77.45 | $104.88 | $64.19 | $60.12 |
| Cost of revenue | $2.65 | |||
| Gross Profit | $74.8 | $104.88 | $64.19 | $60.12 |
| Operating activities | ||||
| Research & development | $214.58 | $193.2 | $195.31 | $190.83 |
| Selling, general & administrative | $63.01 | $42.74 | $46.06 | $40.5 |
| Total operating expenses | $277.59 | $235.94 | $241.37 | $231.33 |
| Operating income | -$202.79 | -$131.06 | -$177.19 | -$171.21 |
| Income from continuing operations | ||||
| EBIT | -$202.12 | -$129.74 | -$151.81 | -$171.45 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$202.12 | -$129.74 | -$151.81 | -$171.45 |
| Income (for common shares) | -$202.12 | -$129.74 | -$151.81 | -$171.45 |
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Net income | -$66.44 | -$58.02 | -$52.89 | -$39.94 |
| Operating activities | ||||
| Depreciation | $2.91 | $2.95 | $2.8 | $2.78 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.27 | $5.41 | $6.36 | $6.07 |
| Total cash flows from operations | -$57.7 | -$54.31 | -$14.79 | -$45.69 |
| Investing activities | ||||
| Capital expenditures | -$1.42 | -$1.38 | -$2.13 | -$2.07 |
| Investments | -$17.07 | -$12.18 | -$0.48 | $15.88 |
| Total cash flows from investing | -$18.48 | -$13.55 | -$2.62 | $13.82 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.04 | -$0.76 | $20.43 | $2.45 |
| Net borrowings | ||||
| Total cash flows from financing | $0.04 | $0.8 | $18.97 | $2.35 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$76.14 | -$67.06 | $1.56 | -$29.53 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$202.12 | -$129.74 | -$151.81 | -$171.45 |
| Operating activities | ||||
| Depreciation | $11.26 | $11.96 | $10.85 | $8.28 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $23.13 | $20.68 | $19.57 | $16.52 |
| Total cash flows from operations | -$143.83 | -$111.9 | -$134.27 | -$153.23 |
| Investing activities | ||||
| Capital expenditures | -$6.2 | -$5.91 | -$4.29 | -$24.95 |
| Investments | -$30.41 | -$1.88 | -$75.07 | $81.6 |
| Total cash flows from investing | -$36.61 | -$7.79 | -$79.36 | $56.64 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $122.78 | $174.34 | $119.97 | $104.99 |
| Net borrowings | ||||
| Total cash flows from financing | $122.78 | $174.34 | $119.97 | $104.99 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$57.66 | $54.66 | -$93.66 | $8.4 |
News
|
James Karrels Is The Senior VP of MacroGenics, Inc. (NASDAQ:MGNX) And They Just Picked Up 26% More...
Simply Wall St. via Yahoo Finance
19 Jun 2022
|
|
50 Stocks Moving In Wednesday's Mid-Day Session
Benzinga
4 May 2022
|
|
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance
3 May 2022
|
|
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
Benzinga
28 Feb 2022
|
|
45 Stocks Moving In Friday's Mid-Day Session
Benzinga
25 Feb 2022
|
|
MacroGenics (MGNX) Reports Q4 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance
24 Feb 2022
|
|
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings...
Benzinga
24 Feb 2022
|
|
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead...
Benzinga
20 Feb 2022
|
|
Quidel (QDEL) Tops Q4 Earnings and Revenue Estimates
Entrpreneur
17 Feb 2022
|
|
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
Zacks via Yahoo Finance
17 Feb 2022
|
Fundamentals
| Market cap | $187.07M |
|---|---|
| Enterprise value | $164.09M |
| Shares outstanding | 61.33M |
| Revenue | $71.67M |
|---|---|
| EBITDA | -$205.84M |
| EBIT | -$217.29M |
| Net Income | -$217.29M |
| Revenue Q/Q | -34.24% |
| Revenue Y/Y | -33.69% |
| P/E ratio | -0.86 |
|---|---|
| EV/Sales | 2.29 |
| EV/EBITDA | -0.80 |
| EV/EBIT | -0.76 |
| P/S ratio | 2.61 |
| P/B ratio | 1.05 |
| Book/Share | 2.91 |
| Cash/Share | 0.77 |
| EPS | -$3.54 |
|---|---|
| ROA | -61.00% |
| ROE | -84.52% |
| Debt/Equity | 0.40 |
|---|---|
| Net debt/EBITDA | -0.22 |
| Current ratio | 3.25 |
| Quick ratio | 3.18 |